American Journal of Kidney Diseases CPR 3.5. Evaluating and Correcting Persistent Failure to Reach or Maintain Intended Hb    American Journal of Kidney Diseases  Volume 47, Pages S81-S85 (May 2006) DOI: 10.1053/j.ajkd.2006.03.019 Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 17 Exposure to Eprex® and case counts of PRCA. Relationship between reporting rate of new cases of PRCA and route of administration (SC versus IV), stabilizer (human serum albumin versus polysorbate 80), and coated versus uncoated stoppers in preparations of Eprex®, a form of epoetin alfa marketed outside the United States. Reprinted with permission.275 American Journal of Kidney Diseases 2006 47, S81-S85DOI: (10.1053/j.ajkd.2006.03.019) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

Fig 18 Mean epoetin dose per patient per administration by percentile of dose (1st, 5th to 95th, and 99th). Data are for December 2004, courtesy of USRDS. American Journal of Kidney Diseases 2006 47, S81-S85DOI: (10.1053/j.ajkd.2006.03.019) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions